Clinical Trials
28 trialsRandomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
ANGLeD
Angiochem Inc
CASA
ETOP IBCSG Partners Foundation
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Austrian Breast & Colorectal Cancer Study Group
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
West German Study Group
TACT2
Institute of Cancer Research, United Kingdom
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
National Cancer Institute, Naples
22-00
ETOP IBCSG Partners Foundation
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
GBG Forschungs GmbH
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
National Cancer Institute (NCI)
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer
National Cancer Institute (NCI)
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
National Cancer Institute (NCI)
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
National Cancer Institute (NCI)
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
National Cancer Institute (NCI)
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
15-95
ETOP IBCSG Partners Foundation
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Taiho Pharmaceutical Co., Ltd.
A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)
Taiho Pharmaceutical Co., Ltd.
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
SCRI Development Innovations, LLC
Study of Docetaxel in Breast Cancer Patients
Sanofi